RPRX

Insider Trades

Name	Value	Action	Price	Current Price
Norden GregoryDirector $1.2M33.5k shares SellAug 11, 2025 $36.23 --
Coyne Terrance P.EVP & CFO $147k3.8k shares SellNov 17, 2025 $39.30 --
Coyne Terrance P.EVP & CFO $2.6M65.8k shares SellNov 17, 2025 $39.30 --
Lloyd George W.EVP, Investments & CLO $179k4.6k shares SellNov 19, 2025 $39.01 --
Lloyd George W.EVP, Investments & CLO $96k2.5k shares SellNov 19, 2025 $39.01 --
Lloyd George W.EVP, Investments & CLO $9.0k230 shares SellNov 19, 2025 $39.03 --

News

etftrends.comHealthcare ETFs: From Broad Exposure to Big Breakthroughsetftrends.comJun 11

seekingalpha.comRoyalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 9

zacks.comGSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyoutzacks.comJun 9

seekingalpha.comDividend Champion, Contender, And Challenger Highlights: Week Of June 7seekingalpha.comJun 5

globenewswire.comRoyalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conferenceglobenewswire.comJun 4

Trade RPRX

About Royalty Pharma plc

Royalty Pharma plc, headquartered in New York City and founded in 1996, operates within the United States as a key player in the biopharmaceutical industry. The company primarily focuses on the acquisition of royalties from biopharmaceutical products and actively invests in funding new developments and innovations in the sector. Its activities involve diligently identifying, evaluating, and securing royalty agreements for a wide array of biopharmaceutical therapies. Beyond acquisitions, Royalty Pharma plc fosters collaborations with various innovators. These partners include academic institutions, research hospitals, non-profit organizations, small and mid-sized biotechnology firms, and larger pharmaceutical companies. The firm's substantial portfolio includes royalty interests in approximately 35 commercially available treatments and an additional 10 product candidates currently in different stages of development. These assets span a diverse range of critical therapeutic areas, such as rare diseases, cancer, neurological conditions, infectious diseases, hematology, and diabetes.

CEO: Pablo Legorreta
IPO Date: Jun 16, 2020

Market Data

Open: $54.38
High: $54.38
Low: $51.15
Volume: 8.6M
Avg Volume: 3.7M
52W High: $56.50
52W Low: $34.08

Valuation

Market Cap: $23B
Enterprise Value: $31B
Dividend Yield: 91.0%

Financials

Free Cash Flow: $2.5B
Revenue: $2.4B
Net Income: $771M
Cash: $619M
Debt: $9.0B

Events

EarningsAug 5

EPS est. 1.27